Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joyce Wald

Advanced Heart Failure and Transplant Cardiology Philadelphia, PA Doctor of Osteopathy

NPI 1275522120 CMS profile 194010

3400 Civic Center Blvd, East Pavilion, 2Nd Floor, Philadelphia, PA 19140

Open in the dashboard

General payments

$96,902

423 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$168,181 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Joyce Wald of Philadelphia, PA is reported in the CMS Open Payments database as having received $96,902 across 423 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $168,181 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $21,963 77
2024 General $22,505 83
2023 General $18,759 82
2022 General $23,533 108
2021 General $7,865 35
2020 General $743 12
2019 General $1,534 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joyce Wald
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Joyce Wald were reported at $21,963. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Joyce Wald Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $1,534 $863 $224–$4,562 $163
2020 $743 $452 $122–$3,992 $114
2021 $7,865 $550 $159–$3,571 $132
2022 $23,533 $729 $221–$4,357 $149
2023 $18,759 $1,002 $309–$5,827 $160
2024 $22,505 $931 $273–$5,204 $164
2025 $21,963 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abiomed $30,100 92 payments
  2. Impulse Dynamics (USA) Inc. $24,292 63 payments
  3. Abbott Laboratories $21,686 140 payments
  4. Boston Scientific Corporation $12,788 21 payments
  5. Medtronic, Inc. $4,755 15 payments
  6. Medtronic Vascular, Inc. $1,014 13 payments
  7. CVRx, Inc. $746 14 payments
  8. Kestra Medical Technology Services, Inc. $457 14 payments
  9. Novartis Pharmaceuticals Corporation $421 36 payments
  10. Daxor Corporation $128 1 payment
  11. Other $515 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $34,900 12 payments
  2. Consulting Fee $28,420 14 payments
  3. Food and Beverage $18,549 355 payments
  4. Travel and Lodging $11,445 41 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,588 1 payment
Products named General payments · program years 2019–2025
  1. Impella $23,126 67 payments
  2. OPTIMIZER Cardiovascular Device $21,101 47 payments
  3. OPTIMIZER Cardiovascular Device $21,101 47 payments
  4. MITRACLIP $8,221 14 payments
  5. General - Structural Heart $5,000 1 payment
  6. CentriMag $4,937 9 payments
  7. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $4,451 65 payments
  8. Optimizer Cardiovascular $3,105 14 payments
  9. Optimizer Cardiovascular $3,073 13 payments
  10. CardioMEMS HF System $1,920 2 payments
  11. Other $7,175 165 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

3,485

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$846,895

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

20.5%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 361 $480,854
Farxiga Dapagliflozin Propanediol Brand 130 $135,356
Jardiance Empagliflozin Brand 75 $90,024
Eliquis Apixaban Brand 29 $39,823
Sildenafil Citrate Generic 57 $34,514
Vascepa Icosapent Ethyl Brand 13 $7,927
Metoprolol Succinate Generic 409 $7,038
Bumetanide Generic 78 $5,593
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 12 $5,546
Carvedilol Generic 357 $4,646

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$88,252

Medicare's payments for the services billed

Medicare patients

415

Average age 70

Services billed

1,741

156 women, 259 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 67%
Atrial fibrillation 55%
Chronic kidney disease 55%
Diabetes 46%
Arthritis 42%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTRESTO
  • Novartis Pharmaceuticals Corporation $119
$119 361 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $115
$115 — —
Repatha
  • Amgen Inc. $24
$24 — —
JARDIANCE
  • Lilly USA, LLC $15
$15 75 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

423 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record